Capital Investment Advisors LLC Raises Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Capital Investment Advisors LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 2.2% in Q2, now holding 434,565 shares valued at $66.38 million, making it the 20th largest position in their portfolio.
• Analysts have raised their price targets for Johnson & Johnson, with the consensus now set at $181.40 and a majority rating of "Moderate Buy" from various brokerages.
• Johnson & Johnson recently declared a quarterly dividend of $1.30, which represents a yield of 2.8% and reflects a payout ratio of 55.61%.

Capital Investment Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 434,565 shares of the company's stock after purchasing an additional 9,532 shares during the quarter. Johnson & Johnson makes up 1.2% of Capital Investment Advisors LLC's portfolio, making the stock its 20th biggest holding. Capital Investment Advisors LLC's holdings in Johnson & Johnson were worth $66,380,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Bennett Selby Investments LP increased its stake in Johnson & Johnson by 3.2% in the second quarter. Bennett Selby Investments LP now owns 18,125 shares of the company's stock valued at $2,769,000 after purchasing an additional 567 shares during the last quarter. Presper Financial Architects LLC acquired a new position in Johnson & Johnson in the second quarter valued at $278,000. Raleigh Capital Management Inc. increased its stake in Johnson & Johnson by 7.3% in the second quarter. Raleigh Capital Management Inc. now owns 14,777 shares of the company's stock valued at $2,257,000 after purchasing an additional 1,005 shares during the last quarter. Claris Advisors LLC MO increased its stake in Johnson & Johnson by 57.4% in the second quarter. Claris Advisors LLC MO now owns 3,437 shares of the company's stock valued at $525,000 after purchasing an additional 1,254 shares during the last quarter. Finally, Smith Chas P & Associates PA Cpas increased its stake in Johnson & Johnson by 2.4% in the second quarter. Smith Chas P & Associates PA Cpas now owns 259,477 shares of the company's stock valued at $39,635,000 after purchasing an additional 6,126 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on JNJ. Morgan Stanley upped their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. UBS Group upped their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada upped their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $181.40.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $185.40 on Wednesday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $185.99. The business has a 50-day moving average of $175.11 and a 200-day moving average of $162.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $446.51 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 2.31 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.